🇺🇸 Valsartan + Amlodipine besilate in United States
13 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 13
Most-reported reactions
- Pain In Jaw — 2 reports (15.38%)
- Renal Failure — 2 reports (15.38%)
- Rotator Cuff Syndrome — 2 reports (15.38%)
- Abdominal Pain — 1 report (7.69%)
- Adrenal Insufficiency — 1 report (7.69%)
- Ageusia — 1 report (7.69%)
- Angina Pectoris — 1 report (7.69%)
- Anosmia — 1 report (7.69%)
- Appendicitis — 1 report (7.69%)
- Aptyalism — 1 report (7.69%)
Other Cardiovascular approved in United States
Frequently asked questions
Is Valsartan + Amlodipine besilate approved in United States?
Valsartan + Amlodipine besilate does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Valsartan + Amlodipine besilate in United States?
Novartis is the originator. The local marketing authorisation holder may differ — check the official source linked above.